Results 21 to 30 of about 1,641 (192)

Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin [PDF]

Infection and Drug Resistance, 2018
Elda Righi, Alessia Carnelutti, Antonio Vena, Matteo Bassetti Infectious Diseases Division, Santa Maria della Misericordia University Hospital, Udine, Italy Abstract: The increase in hospitalization due to acute bacterial skin and skin ...
Righi E, Carnelutti A, Vena A, Bassetti M   +3 more
doaj   +5 more sources

Novel use of oral delafloxacin monotherapy in staphylococcal prosthetic valve endocarditis: A case report [PDF]

Infectious Medicine
Delafloxacin (DLFX), a new anionic fluoroquinolone, has been approved by the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of bacterial skin and skin structure infections and by the FDA for ...
Antonio Mastroianni, Valeria Vangeli, Giuliana Guadagnino, Luciana Chidichimo, Lavinia Berardelli, Sonia Greco   +5 more
doaj   +2 more sources

Using delafloxacin, a 4th generation fluoroquinolone, in combination with nebulised tobramycin to eradicate Pseudomonas aeruginosa in cystic fibrosis [PDF]

Respiratory Medicine Case Reports
Prompt eradication of Pseudomonas aeruginosa following isolation in sputum samples is a fundamental part of therapy in people with cystic fibrosis in order to prevent chronic infection. Whilst multiple eradication regimens exist, none have been proven to
Michael Kevin Dooney, Tarek Saba, Natasha Pickering, Mohamed Etumi   +3 more
doaj   +2 more sources

An evaluation of antibiotic options for the treatment of biothreat pathogens [PDF]

Frontiers in Antibiotics
The development of medical countermeasures against pathogens of biodefense concern remains critical to protecting military and public health. This review compares data detailing antibacterial activity and efficacy for a selection of antibiotics evaluated
J. Matthew Meinig, Michelle Nelson, Christopher K. Cote, Stevan R. Emmett, Sarah V. Harding, Sarah V. Harding   +5 more
doaj   +2 more sources

Role of parC Mutations at Position 84 on High-Level Delafloxacin Resistance in Methicillin-Resistant Staphylococcus aureus [PDF]

Antibiotics
High-level delafloxacin-resistant (H-L DLX-R) Staphylococcus aureus isolates (minimum inhibitory concentration ≥1 mg/L) associated with mutations affecting position 84 of ParC have emerged. We aimed to elucidate the role of these mutations as a mechanism
Silvia Bolaños, Cesar Acebes, Óscar Martínez-Expósito, José Antonio Boga, Javier Fernández, Carlos Rodríguez-Lucas   +5 more
doaj   +2 more sources

Fluoroquinolone-Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real-World Data From FAERS (2011-2024). [PDF]

Pharmacol Res Perspect
This pharmacovigilance study identifies a wide range of rapid‐onset neuropsychiatric and ocular adverse effects linked to fluoroquinolones (FQ). Disproportionality analysis revealed a disproportionate reporting of suicidal ideation and visual impairment following FQ treatment, emphasizing the urgent need for cautious prescribing and strengthened safety
Chau HT, Au NPB.
europepmc   +2 more sources

In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species

Microbiology Spectrum, 2022
The in vitro activity of two new fluoroquinolones, delafloxacin and finafloxacin, were evaluated against M. hominis and Ureaplasma spp. The MICs of delafloxacin, finafloxacin, and two classical fluoroquinolones (moxifloxacin and levofloxacin) were tested
Yingying Kong, Chao Li, Gangfeng Li, Ting Yang, Mohamed S. Draz, Xinyou Xie, Jun Zhang, Zhi Ruan   +7 more
doaj   +1 more source

Delafloxacin––A novel fluoroquinolone for the treatment of ciprofloxacin‐resistant Pseudomonas aeruginosa in patients with cystic fibrosis

The Clinical Respiratory Journal, 2021
Introduction Fluoroquinolone antibiotics, namely ciprofloxacin and levofloxacin, play an important role in treating infection in cystic fibrosis (CF) and ciprofloxacin remains the last widely used and orally available antipseudomonal agent.
Beverley Cherie Millar, John McCaughan, Jacqueline C. Rendall, John E. Moore   +3 more
doaj   +1 more source

Investigation of Delafloxacin Resistance in Multidrug-Resistant Escherichia coli Strains and the Detection of E. coli ST43 International High-Risk Clone

Microorganisms, 2023
Delafloxacin is a novel fluoroquinolone agent that is approved for clinical application. In this study, we analyzed the antibacterial efficacy of delafloxacin in a collection of 47 Escherichia coli strains.
Dániel Gulyás, Katalin Kamotsay, Dóra Szabó, Béla Kocsis   +3 more
doaj   +1 more source

The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials

Frontiers in Pharmacology, 2022
Background: This study aims to assess the clinical efficacy and adverse events of delafloxacin for the treatment of acute bacterial infections in adult patients through meta-analysis.Methods: The PubMed, Embase, Cochrane library, Web of Science, and ...
Rong He, Fei Lin, Fei Lin, Bin Yu, Jingyue Qiu, Lingli Zheng   +5 more
doaj   +1 more source